Zelenectide pevedotin
- Generic Name
- Zelenectide pevedotin
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Phase 2
Recruiting
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 956
- Registration Number
- NCT06225596
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Virginia K. Crosson Cancer Center at St. Jude Medical Center, Fullerton, California, United States
🇺🇸University of California - Irvine Medical Center, Orange, California, United States
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Phase 1
Recruiting
- Conditions
- Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative NeoplasmsHormone Receptor Positive, HER2-low NeoplasmsBreast NeoplasmsNon-Small-Cell Lung NeoplasmsOvarian NeoplasmAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 329
- Registration Number
- NCT04561362
- Locations
- 🇫🇷
Centre Eugene Marquis, Rennes, France
🇫🇷Institut Bergonie, Bordeaux, France
🇫🇷Institut Gustave Roussy, Villejuif, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath